Company History

Founded in 1996 in Sweden as Cortendo AB, our original focus was on regulating cortisol secretion in patients with diabetes.

In the course of reinventing, refocusing, and reinvigorating the company, Strongbridge Biopharma has reached a series of pivotal business and clinical milestones.

2016: An Important Year for Strongbridge

In December 2016, Strongbridge Biopharma acquired the US rights to KEVEYIS® (dichlorphenamide). This acquisition is part of our commitment to expand our portfolio and help meet the needs of patients with rare and orphan diseases that are underdiagnosed and undertreated.

Key Milestones

Recent clinical milestones reflect our focus on rare diseases and our organizational agility in meeting the challenges of drug development.

For KEVEYIS important safety information, please see full Prescribing Information (PDF).

Learn more about our investigational therapies

RECORLEV (levoketoconazole) and veldoreotide

© 2017 Strongbridge Biopharma plc
STRONGBRIDGE BIOPHARMA is a trademark of Strongbridge Biopharma plc.
KEVEYIS® is a registered trademark licensed exclusively in the US to Strongbridge Biopharma plc.
MLR010 V7 12/2016

900 Northbrook Drive, Suite 200
Trevose, PA 19053
United States
Phone: +1 610-254-9200
info@strongbridgebio.com

Comprehensive Compliance Program
California Statement of Compliance